Interventional Studies Is Expected To Be The Highest Revenue Generating Segment In Omics Based Clinical Trials Market

Newly-released Omics Based Clinical Trials Market analysis report by Fact.MR shows that global sales of Omics Based Clinical Trials Market in 2021 was held at US$ 26.2 Bn. With 8.1%, the projected market growth during 2022 – 2032 is expected to be significantly higher than the historical growth. Interventional Studies is expected to be the highest revenue generating segment, accounting for an absolute dollar opportunity of nearly US$ 26.6 Bn during 2022 – 2032.

To remain ‘ahead’ of your competitors, request for a sample –

The constant surge in demands for Omics-Based Clinical Trials is due to Covid-19 pandemic. The main drivers were rising investment in the pharmaceutical industry by the prominent participants to enhance their productivity, rising demand for omics-based clinical trials, and increasing prevalence of chronic disorders. Owing to this, Omics Based Clinical Trials Markets is projected to grow at a CAGR of 8.1% over the coming 10 years.

  • Omics-Based Clinical Trials Market was valued at US$ 26.2 Bn in 2021. Covid 19 emerged as a turning point for Omics Based Clinical Trials Market and it grew at a 7.5% annual pace compared to the previous year 2020, wherein the valuation was US$ 24.2Bn. According to Fact.MR, Omics Based Clinical Trials Market revenue is projected to increase 2.2X times between 2022 and 2032, reaching roughly US$ 61.7 Bn in 2032.
  • In terms of Study Design, the sub-segment Interventional Studies accounts for more than 75% of the market.
  • In terms of Indication, Oncology, Cardiology and Respiratory Diseases accounted for a combined share of 58.3%.
  • North America is the dominant region in Omics Based Clinical Trials Markets with absolute dollar opportunity of US$ 13.4 Bn during the forecast period.

Need more information about Report Methodology? Ask here –

Omics Based Clinical Trials Market Report Scope

Forecast Period2022-2032
Historical Data Available for2017-2021
Market AnalysisUS$ Bn for Value
Key Regions CoveredNorth AmericaLatin AmericaEuropeAsia PacificMiddle East & Africa
Key Countries CoveredUnited StatesCanadaBrazilMexicoGermanyU.K.FranceSpainItalyRussiaChinaJapanSouth KoreaIndiaAustraliaSouth AfricaSaudi ArabiaUAEIsrael
Key Market Segments CoveredPhaseStudy DesignIndicationRegion
Key Companies ProfiledParexel International CorporationPharmaceutical Product Development (PPD)Charles River LaboratoryICON plcSGS SAEli Lilly and CompanyPfizer Inc.Covance Inc.Rebus Bio
Full Access of this Exclusive Report is Available at-

Owing to the ease of regulatory compliance, low study costs, growing patient population, and the existence of a few elite clinical institutions acting as sites, Asia-Pacific has become a hotspot for conducting clinical trials. Omics Based Clinical Trials Market revenue is estimated to expand at the fastest rate in APAC between 2022 and 2032, with a projected growth rate of around 9.0%. China’s regulatory bodies, for example, are attempting to improve the clinical trial process by shortening the total review and approval procedure.

Competitive Analysis

Due to the presence of a large number of developed as well as medium to small-sized organisations, the market for omics-based clinical trials is significantly competitive. A number of market participants are privately held or are part of the portfolios of private equity companies. Some of the key prominent players in the Omics Based Clinical Trials market include: Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Covance Inc., Novo Nordisk, Rebus Bio.

For Trending Updates of Fact.MR , Check out the Link:

About Fact.MR:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

About the Author

Leave a Reply

Your email address will not be published.

You may also like these